Investigating how mitochondrial NAD+ affects Acute Myeloid Leukemia
Official title: Mitochondrial NAD+ in Acute Myeloid Leukemias
Funded at University of Texas at Austin · NIH-10913369 · Data updated 2026-11-12
This study is looking at how certain cancer cells in Acute Myeloid Leukemia (AML) use a special nutrient for their growth, and it aims to find a way to block that nutrient to make the cancer cells less able to survive and grow, which could help create better treatments that are kinder to healthy cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project start | August 24, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $496,412 |
| NIH project number | 5R01CA272490-02 |
| Project ID | NIH-10913369 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with Acute Myeloid Leukemia, particularly those who may have developed resistance to current treatments.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with Acute Myeloid Leukemia may not benefit from this research.
What this research studies
This research focuses on understanding the role of mitochondrial metabolism in Acute Myeloid Leukemia (AML), particularly how AML cells utilize mitochondrial NAD+ for their growth and survival. The researchers aim to selectively deplete mitochondrial NAD+ in AML cells by targeting a specific transporter, SLC25A51, which is crucial for NAD+ import into mitochondria. By blocking multiple metabolic pathways simultaneously, the study seeks to reduce the adaptability of AML cells and potentially overcome treatment resistance. This approach could lead to more effective therapies with minimal toxicity to healthy cells.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively target AML cells while sparing healthy cells, improving patient outcomes.
How similar studies have gone: While targeting mitochondrial metabolism in cancer is an emerging field, this specific approach using SLC25A51 to deplete mitochondrial NAD+ has not been extensively tested, making it a novel investigation.
Where this research is happening
-
University of Texas at Austin
Austin, United States Active
Researchers
- Principal investigator: Cambronne, Xiaolu Ang — University of Texas at Austin
- Study coordinator: Cambronne, Xiaolu Ang
Related research
Other NIH-funded projects on the same topics.
-
Translating new nerve grafts to clinical use
Aims to bring advanced nerve graft technology that uses PEG-fusion and localized immunosuppression to patients with nerve gaps.
-
GABA-A receptor gating mechanisms and how drugs affect them
Researchers are studying how GABA-A receptor gates work and how medicines can modulate them to help people with epilepsy, Alzheimer's-related symptoms, and other brain disorders.
-
Nanoparticles that calm inflammation after artery procedures
A new nanoparticle inspired by dying cells is being tested to reduce inflammation after artery procedures and help PAD patients heal better.
-
Silent speech interface using a wearable tongue tracker to help people after laryngectomy communicate
A wearable system with tongue sensors and intraoral components aims to let people without a vocal cord use natural-sounding speech in daily life.
-
Understanding and reversing abnormal brain activity in Alzheimer's disease
Aims to understand how unusual brain activity contributes to Alzheimer’s and test ways to reverse it to help people with the condition.
-
CFDE Cloud Workspace to help researchers share and analyze data
A cloud-based workspace will let a wide range of researchers import, integrate, and analyze data from CFDE and other sources using familiar tools and workflows.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.